- The PBAC met in November to review a proposed amendment to allow nurse practitioners to prescribe certain MS treatments under the PBS.
- The PBAC has recommended the proposed change, which is a game-changer set to dramatically improve access to care, especially in regional and remote areas.
- This decision marks the first step in a process that will now proceed to the Federal Government for final approval.
The Pharmaceutical Benefits Advisory Committee (PBAC) has announced its position regarding a proposed amendment to allow nurse practitioners to prescribe certain MS treatments under the PBS after its November meeting.
The PBAC is required to consider several factors when making recommendations, including clinical trial data, community submissions, and pricing information. This decision marks the first step in a process that will now proceed to the Federal Government for final approval.
The PBAC has made a groundbreaking recommendation to allow nurse practitioners to prescribe certain MS treatments under the PBS in consultation with a physician, including fingolimod (Gilenya®), ofatumumab (Kesimpta®), and siponimod (Mayzent®). This change is set to dramatically improve access to care, especially in regional and remote areas.
MS Australia welcomes this news and acknowledges that this change is crucial for improving access to care, especially in regional and remote areas where MS care can be limited. MS Australia provided support for this submission to the PBAC, which can be viewed here.
The PBAC submission is based on the findings of the recent MS Nurse Care in Australia report, an initiative of MS Australia, which highlights the crucial role that MS nurses play in managing the condition.
One of the key findings from the report is that access to MS nurses leads to significantly better health outcomes, including slower disease progression and reduced severity of symptoms such as depression and anxiety.
Unfortunately, access to MS care is particularly limited in regional and remote areas, where the shortage of neurologists further intensifies the barriers experienced by people living with MS.
Expanding nurse practitioner prescribing rights for key MS medications will ensure that people with MS in regional and remote areas receive equitable access to the best available therapies. It will also streamline care pathways, reduce the burden on individuals, and improve overall treatment outcomes. This approach would enable timely adjustments to treatment plans, enhancing adherence and ultimately leading to better health outcomes.
MS Australia continues to advocate for systemic changes that will improve the lives of people with MS and MS-related disorders. It remains committed to ensuring that all Australians living with MS and MS-related disorders can benefit from a healthcare system that is inclusive, accessible, and equitable.
